Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug?
- 30 November 2001
- journal article
- review article
- Published by Elsevier in Antiviral Research
- Vol. 52 (2), 139-146
- https://doi.org/10.1016/s0166-3542(01)00178-4
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Two years lamivudine therapy in patients with chronic hepatitis B. Analysis of efficacy and emergence of HBV genomic variationsJournal of Hepatology, 2000
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapyHepatology, 1999
- Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis BHepatology, 1999
- Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatmentHepatology, 1999
- Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfaHepatology, 1997
- Hepatitis B reactivation after lamivudineThe Lancet, 1995
- Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapyJournal of Hepatology, 1992
- Which Patients With Chronic Hepatitis B Virus Infection Will Respond to α–Interferon Therapy? A Statistical Analysis of Predictive FactorsHepatology, 1989
- Histological improvement after anti-viral treatment for chronic hepatitis B virus infectionJournal of Hepatology, 1989